trending Market Intelligence /marketintelligence/en/news-insights/trending/3VoEqvJwrorUGg-QZY3O5Q2 content esgSubNav
In This List

Summa Equity buys majority stake in Olink Proteomics


S&P Capital IQ Pro | Unrivaled Sector Coverage


S&P Capital IQ Pro | Powering Your Edge


Street Talk Episode 81: Amid strong recovery, Banc of California hearing more M&A chatter


Banking Essentials Newsletter: September Edition

Summa Equity buys majority stake in Olink Proteomics

Summa Equity purchased Sweden-headquartered life sciences company Olink Proteomics AB, which has developed technology for human biomarker discovery.

Under the deal, the private equity firm will become the company's majority shareholder, while its founder Ulf Landegren and the management team will continue as stockholders.

Moelis & Co. LLC served as financial adviser to Summa, White & Case was its legal adviser, LEK Consulting was its commercial adviser and KPMG was its accounting adviser. J.P. Morgan Securities LLC acted as financial adviser to Olink, while Wiggin, Dana LLP and Lindahl were its legal advisers.